By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
How to avoid or deal with an outrageous medical bill - 2FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- 3We analyzed Philly street scenes and identified signs of gentrification using machine learning trained on longtime residents’ observations
- 4Brazil's Bolsonaro to continue his sentence at home because of poor health
- 5Medtronic has 'significant firepower' for multiple acquisitions, executives say
- 'A completely new manufacturing frontier': Space Forge fires up 1st commercial semiconductor factory in space
- German men need approval for stays abroad under military service law
- German Winemakers Rewrite The Rules Of Riesling In A Warming World
- Famous Kitchen Finishing Styles For 2024
- The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results
- Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- Netanyahu vows to ‘return Negev to Israel,’ pledges settlement growth during visit
- Katz alleges Army Radio workers misled High Court in bid to halt closure
